Status:
COMPLETED
Trial of Iressa in Prostate Cancer Patients
Lead Sponsor:
AstraZeneca
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
This study is being carried out to see if ZD1839 is effective in treating prostate cancer after being diagnosed with an early rising PSA (prostate specific antigen) following surgery.
Eligibility Criteria
Inclusion
- Removal of prostate for prostate cancer
- Raised level of prostate specific antigen (PSA) post-surgery
- Can have received some radiation therapy
Exclusion
- Any after surgery male hormone blocking therapy.
- Low white blood cell count
- Abnormal liver function test
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00265070
Start Date
January 1 2003
End Date
August 1 2011
Last Update
February 5 2013
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Vancouver, British Columbia, Canada
2
Research Site
London, Ontario, Canada
3
Research Site
Toronto, Ontario, Canada
4
Research Site
Montreal, Canada